{"id":5619,"date":"2010-12-28T09:16:15","date_gmt":"2010-12-28T14:16:15","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=5619"},"modified":"2011-07-19T17:45:20","modified_gmt":"2011-07-19T21:45:20","slug":"looking-forward-to-2011","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/12\/28\/looking-forward-to-2011\/","title":{"rendered":"Looking Forward to 2011"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
CardioExchange invited a wide range of members\u2212researchers, teachers, private practice clinicians, and fellows\u2212to offer predictions for 2011. We summarize their lists here and offer a running scorecard. Click the authors’ names to read the full posts. The same CardioExchange members give us their impressions of the most important developments in cardiology in 2010, and you can see a summary of those here<\/a>. <\/em><\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
What are your predictions for the year? Where have our Nostradamus’ gone wrong?<\/strong><\/p>\n


\n<\/strong><\/td>\n<\/tr>\n

\"\"<\/a>Steven E Nissen, MD<\/strong><\/a>
\n1. Federal investigation of overuse of stents
\n2. ACC announces that it will no longer accept funding from device manufacturers
\n3. Efforts to revise healthcare legislation will fail<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>JoAnne M. Foody, MD<\/strong><\/a>
\n1. More people on statins as they go generic, but fewer actually reaching lipid targets
\n2. Use of biomarkers and pharmacogenomic strategies to mitigate CV risk will take a back seat
\n3. New primary and secondary prevention guidelines will be more aggressive<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Roger Blumenthal, MD <\/strong><\/a>
\n1. Patriots beat Eagles in the Superbowl
\n2. ATP IV and JNC 8 out by next AHA
\n3. CETP inhibition with dalcetrapib is successful in ACS patients.
\n4.IMPROVE-IT shows a modest benefit
\n5. Sanjay Kaul finds a trial design and a DSMB he likes!<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"\"\"Richard A. Lange, MD, MBA and L. David Hillis, MD<\/strong><\/a>
\n1. Government scrutiny of interventional cardiology will increase
\n2. Platelet reactivity assays to guide antiplatelet therapy after PCI will get even more confusing
\n3. New guidelines on which patients benefit from revascularization and what type (PCI vs. CABG) will change little<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Deepak L. Bhatt, MD, MPH<\/strong><\/a>
\n1. Increased focus on costs, increased costs, and emergence of de facto rationing
\n2.Increased scrutiny of cardiac images and procedures yields underutilzation
\n3. Further consolidation among cardiology practices and hospitals<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>John Brush, MD<\/strong><\/a>
\n1. Meaningful payment reform is realized
\n2. ACC will work to implement point-of-care access to appropriate use criteria for imaging tests
\n3. Observational studies will show that the vast majority of interventional procedures are performed appropriately<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>John Mandrola, MD<\/strong><\/a>
\n1. No pill or surgery will treat obesity effetively
\n2. Coronary stents will surpass ICDs in regulatory oversight
\n3. AF will stay on the front page of cardiology news<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>Thad F Waites, MD<\/strong><\/a>
\n1. Healthcare reform is not overturned but implemented slowly
\n2. More groups move to employed status in response to cost-cutting, EHR requirements, etc.
\n3. Hospital to Home National Quality Improvement Initiative is a big success<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>John Ryan, MD<\/strong><\/a>
\n1. 2011 will see a shift away from warfarin
\n2. More healthcare delivery studies focused on decreasing costs and improving quality
\n3. Will JNC-8 have dramatically new recommendations?<\/td>\n<\/tr>\n
\"\"<\/td>\n<\/tr>\n
\"\"<\/a>James De Lemos, MD<\/strong><\/a>
\n1. End of the independent practitioner
\n2. Increased focus on the harm caused by unnecessary radiation exposure
\n3. Increasing public scrutiny around conflict of interest issues<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

CardioExchange invited a wide range of members\u2212researchers, teachers, private practice clinicians, and fellows\u2212to offer predictions for 2011. We summarize their lists here and offer a running scorecard. Click the authors’ names to read the full posts. The same CardioExchange members give us their impressions of the most important developments in cardiology in 2010, and you […]<\/p>\n","protected":false},"author":343,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[635],"class_list":["post-5619","post","type-post","status-publish","format-standard","hentry","category-general","tag-predictions"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/343"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=5619"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5619\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=5619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=5619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=5619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}